Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-18-114220
Filing Date
2018-04-11
Accepted
2018-04-11 16:02:04
Documents
6
Period of Report
2018-05-22
Effectiveness Date
2018-04-11

Document Format Files

Seq Description Document Type Size
1 DEF 14A d508129ddef14a.htm DEF 14A 583850
2 GRAPHIC g508129g39r78.jpg GRAPHIC 27791
3 GRAPHIC g508129g54o15.jpg GRAPHIC 23639
4 GRAPHIC g508129g58n43.jpg GRAPHIC 8319
5 GRAPHIC g508129g64d68.jpg GRAPHIC 12703
6 GRAPHIC g508129g71i24.jpg GRAPHIC 28207
  Complete submission text file 0001193125-18-114220.txt   724016
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-31791 | Film No.: 18750085
SIC: 2834 Pharmaceutical Preparations